Last reviewed · How we verify

Pancreatic Enzyme Replacement Therapy

Anna Evans Phillips · FDA-approved active Small molecule Quality 5/100

Pancreatic Enzyme Replacement Therapy (PERTh) is a marketed product by Anna Evans Phillips, positioned in the treatment of pancreatic insufficiency. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk is the lack of disclosed key trial results and revenue data, which may limit investor confidence and market competitiveness.

At a glance

Generic namePancreatic Enzyme Replacement Therapy
Also known askreon
SponsorAnna Evans Phillips
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: